Drug Type Small molecule drug |
Synonyms Multiple sclerosis program (Proteorex) |
Target |
Action inhibitors |
Mechanism USP15 inhibitors(ubiquitin specific peptidase 15 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Multiple Sclerosis | Preclinical | Canada | 19 May 2017 | |
| Multiple Sclerosis | Preclinical | Canada | 19 May 2017 |





